Email: cspc@cspc.cn
Media
News Center
Jan. 05
2023
Meloxicam Nanocrystal Injection Obtains Clinical Trial Approval
Jan. 04
Highly Selective Prmt5 Inhibitor SYH2045 Obtains Clinical Trial Approval
Dec. 14
2022
CSPC's Innovative Drug Research Results Selected for the 2022 ASH Annual Meeting
The American Society of Hematology (ASH) Annual Meeting will be held in New Orleans, USA, December 10~13, 2022. As the world's largest professional society on the etiology and treatment of blood disorders, the ASH Annual Meeting is one of the largest and most comprehensive international academic events in the field of hematology worldwide.
Dec. 07
Oral Small-Molecule 3CLpro Inhibitor SYH2055 Against SAR-CoV-2 Obtains Clinical Trial Approval
Nov. 29
CSPC Selected as Mercer China Healthiest Workplace
On November 25, 2022, the Award Ceremony for Mercer China Healthiest Workplace 2022-2023 was held in Shanghai, where CSPC was recognized by Mercer as a Healthiest Workplace. Nearly 10,000 people witnessed the moment virtually or in person. On November 25, 2022, the Award Ceremony for Mercer China Healthiest Workplace 2022-2023 was held in Shangh
Antibody-Drug Conjugate Cpo204 Obtains Clinical Trial Approval In The U.S.
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
